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INTRODUCTION
Toluene diisocyanate (TDI) is a very common cause of occu-
pational asthma (OA) worldwide. The pathogenic mechanisms 
of TDI-induced asthma are more variable than those of atopic 
and non-atopic asthma. However, similar to non-OA, OA may 
result from the complicated interactions of multiple genetic and 
environmental factors.
1,2 Genetic factors may modify TDI-in-
duced asthma susceptibility, as seen in previous studies in which 
only 5–15% of isocyanate-exposed workers developed asthma.
3 
The genes for glutathione S-transferase (GSTP1 and GSTM1),
4 
N-acetyltransferase (NAT),
5 HLA classes I and II,
6,7 and neuroki-
nin 2 receptor (NK2R)
8 may all confer susceptibility to or pro-
tection against TDI exposure-associated asthma. β2-adrenergic 
receptor gene (ADRB2) polymorphisms have been identified, 
which are functionally relevant and may modify disease; numer-
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ous clinical studies have described the effects of such polymor-
phisms on asthma and related phenotypes.
9,10 The ADRB2 is a 
small, intronless gene that has recently been resequenced in 
multiple ethnic populations to determine polymorphic variabil-
ity and haplotype structure.
11 Two ADRB2 single nucleotide poly-
morphisms (SNPs) at codons 16 and 27 are frequently associat-
ed with the asthmatic phenotype; the Gly16 variant is positively 
associated with severe and nocturnal asthma.
9,12,13 Isocyanates 
may act as pharmacological inhibitors of β2-adrenergic recep-
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Purpose:  A genetic polymorphism of the beta 2-adrenergic receptor is a major factor associated with the asthmatic phenotype. The association of 
this polymorphism with toluene diisocyanate (TDI)-induced asthma has not been investigated. We examined 103 TDI-induced asthma patients (TDI-
OA), 60 asymptomatic exposed controls (AEC), and 263 unexposed healthy controls (NC) in order to identify beta 2-adrenergic receptor gene (ADRB2) 
polymorphisms and the possible association with TDI-induced asthma. Methods:  Single nucleotide polymorphisms (SNPs) of ADRB2 were geno-
typed by direct sequencing. Serum-specific IgE and IgG levels were measured using an enzyme-linked immunosorbent assay. Phenotypes and clinical 
patient parameters were compared. Results:  SNPs were identified (−47 T>C, −20 T>C, Arg16Gly A>G, Gln27Glu C>G, Leu134Leu G>A, Arg175Arg 
C>A) during ADRB2 screening (from –231 to 793 bp). No significant differences in allelic and genotypic frequencies were noted for any of the six ADRB2 
SNPs. The Arg16Gly A>G, Leu134Leu G>A, and Arg175Arg C>A SNPs and haplotype 1 [TTACGC] were significantly associated with specific IgE anti-
bodies to the TDI-human serum albumin (HSA) conjugate in TDI- exposed subjects (P<0.05). Exposed workers with the ADRB2 ht1/ht1 homozygote 
had a significantly higher TDI-HSA conjugate-specific IgE sensitization rate than did those with the null ht1 haplotype (odds ratio, 15.40; 95% confi-
dence interval, 1.81–131.06). Conclusions:  ADRB2 polymorphisms may affect IgE-specific sensitization to TDI-HSA conjugate in TDI-exposed 
workers.
Key Words:  Isocyanate; asthma; β2-adrenergic receptor; specific IgE; genetic susceptibility
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correspondence to:  Hae-Sim Park, MD, PhD, Department of Allergy and 
Rheumatology, Ajou University School of Medicine, San 5 Woncheon-dong, 
Yongtong-gu, Suwon 443-721, Korea.
Tel: +82-31-219-5196; Fax: +82-31-219-5154; E-mail: hspark@ajou.ac.kr
Received: April 12, 2010; Accepted: June 14, 2010
•There are no financial or other issues that might lead to conflict of interest.ADRB2 Polymorphisms in TDI-Induced Asthma AAIR 
Allergy Asthma Immunol Res. 2010 October;2(4):260-266.  doi: 10.4168/aair.2010.2.4.260 261 http://e-aair.org
tors in TDI-OA by affecting the ability to produce cyclic adenos-
ine monophosphate and to maintain bronchial tone.
14,15 A pre-
vious study established that β2-adrenergic receptor stimulation 
inhibited release of proinflammatory mediators from mast cells 
and influenced T-cell growth and function as well as eosinophil 
survival and function.
16 Therefore, many lung cell types impli-
cated in asthma pathogenesis are potentially influenced by β2-
adrenergic receptor signals. Previous studies have identified 
pharmacoethnic differences between Korean and Caucasian 
populations in the ADBR2 genotype distribution and the phar-
macogenetic association of responses to β2-agonists.
17-19
No studies to date have evaluated ADRB2 polymorphisms as 
possible disease modifiers in TDI-OA. To our knowledge, this is 
the first investigation to evaluate the genetic association of ADRB2 
polymorphisms with the TDI-OA phenotype in a Korean popu-
lation.
MATERIALS AND METHODS
Subjects
Patients with confirmed TDI-OA (n=103) were included in the 
study. Patients were primarily diagnosed by positive responses 
to TDI bronchoprovocation tests. TDI-exposed asymptomatic 
workers (n=60) were enrolled from work environments with 
similar intensities of TDI exposure (spray painters, furniture pol-
ishers, and musical instrument factory workers) and comprised 
the asymptomatically exposed control group (AEC). A total of 
263 unexposed healthy control subjects (NC) were recruited 
from the volunteer population. All subjects provided informed 
consent and the study was approved by the Institutional Review 
Board of Ajou Medical Center, Suwon, Korea.
The demographic data for the three study groups are summa-
rized in Table 1. Atopy was determined by a positive skin test to 
at least one common inhalant allergen. The battery of allergens 
included the house dust mite, tree and pollen mixtures, mugwort, 
ragweed pollens, and alternaria (Bencard, Worthing, West Sus-
sex, UK). Serum samples from TDI-OA individuals were collect-
ed at initial diagnosis during the exposure period; all participants 
discontinued inhaled or oral steroids 4 weeks prior to the start 
of the study. Participants in the TDI-OA and NC groups under-
went an interview, chest radiography, and skin prick test with 
common inhalant allergens. Pulmonary function measurements 
and methacholine inhalation challenge were performed in TDI- 
OA subjects.
Bronchial challenge test with methacholine and TDI
The methacholine bronchial challenge test was performed in 
TDI-OA patients as described previously.
20 Briefly, aerosols were 
generated with a DeVilbiss 646 nebulizer connected to a DeVil-
biss dosimeter driven by compressed air (DeVilbiss Co., Doyle-
stown, PA, USA). Normal saline inhalation at 5-minutes inter-
vals was followed by a series of progressively increasing doses 
of methacholine (0.075–25 mg/mL) until a 20% fall in forced ex-
piratory volume in the first second (FEV1) was observed or un-
til the maximum dosage was reached. FEV1 was measured 5 
minutes after the initiation of each set of aerosolized metha-
choline inhalation. The methacholine concentration resulting 
in a 20% fall in FEV1 (PC20) was determined by interpolation 
from the dose-response curve. The TDI bronchial challenge 
test was performed according to the procedure described pre-
viously.
20
Specific IgG and IgE antibodies to TDI-HSA conjugate 
determined by ELISA
The vapor-type TDI-human serum albumin (HSA) conjugate 
was prepared from 80% 2,4-TDI isomers based on the recently 
described isocyanate vapor-phase exposure system.
21,22 Serum-
specific IgE and IgG levels were determined by enzyme-linked 
immunosorbent assay (ELISA), as described previously.
21 Briefly, 
TDI-albumin conjugate (1 μg) or mock conjugate was dissolved 
in normal saline and used to coat ELISA plates (Corning, New 
York, NY, USA) at 37°C for 2 hours, followed by overnight incu-
bation at 4°C. Plates were washed with PBS-Tween 20 (PBS-T), 
and blocked with blocking buffer (350 μL, PBS containing 5% 
BSA and 0.05% Tween 20). Sera from patients and control sub-
jects were diluted 1:5 for specific IgG measurements and at 1:3 
for specific IgE; sera (50 μL) were incubated in TDI-albumin- 
and mock albumin-coated wells for 1 hour at 25°C. Plates were 
washed four times, and alkaline phosphatase-conjugated anti-
IgG antibody (1:20,000, 100 μL; Sigma, St. Louis, MO, USA) or 
goat anti-IgE (1:1,000; Kirkegaard and Perry Laboratories, 
Gaithersburg, MD, USA) and alkaline phosphatase-conjugated 
rabbit anti-goat IgG antibody (1:200; Kirkegaard and Perry Lab-
Table 1.  Clinical characteristics of the study subjects
Parameter
TDI-OA
(n=103)
AEC
(n=60)
NC
(n=263)
Age (yr)* 41.3±9.8 41.7±7.6 34.1±14.3
Sex (male/female)* 69/34 45/15 96/167
Atopy* 35/75 (46.7%) NA 33/192 (17.2%)
Exposure duration (yr)
† 7.1±4.9 12.0±7.3 NA
FEV1 (%) 85.7±20.4 90.2±20.2 NA
PC20 methacholine
  (mg/mL)
4.9±7.9 NA NA
Serum total IgE (IU/mL)* 284.8±4346.7 265.7±584.9 102.3±167.6
Specific IgG to TDI-HSA 17/70 (24.3%) 7/60 (11.7%) NA
Specific IgE to TDI-HSA
† 19/70 (27.1%) 4/60 (6.7%) NA
Results are expressed as the mean±SD.
FEV1 and PC20 were measured at initial diagnosis.
*P<0.01, for TDI vs. NC; 
†P<0.01, for TDI vs. AEC.
TDI-OA, toluene diisocyanate-induced asthma patients; AEC, asymptomatic ex-
posed controls; NC, normal controls; n, number of subjects; NA, not available; 
PC20, the provocative dose of methacholine required to produce a 20% fall in 
FEV1.Ye et al. Volume 2, Number 4, October 2010
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oratories) was added to each well and incubated for 1 hour at 
room temperature. Plates were washed, and substrate solution 
(100 μL) was added to each well (Sigma); plates were incubated 
for 30 minutes at room temperature. The absorbance at 405/450 
nm was determined using an ELISA plate reader. Specific TDI 
binding was calculated as the difference in optical density be-
tween mock-conjugated and the TDI-albumin wells.
Identification and genotyping of single nucleotide 
polymorphisms
The ADRB2 gene fragment containing the promoter and exon 
1 (1,483 bp) was sequenced to examine SNPs in DNA samples 
from subjects. DNA sequencing was performed using an ABI 
Prism 3100 DNA analyzer (Applied Biosystems, Foster City, CA, 
USA). Primers (5΄-CCTAAAGTCCTGTGCACATAAC-3΄ and 
5΄-GCCCTCAGATTTGTCAATCTTC-3΄) were designed for am-
plification and sequencing. The PCR mix (30 μL) contained 
primers (10 pmol), dNTPs (1 μM), and Taq DNA polymerase (1 
U). The amplification program included a single cycle at 94°C 
for 5 minutes followed by 35 cycles of 94°C for 30 seconds, 60°C 
for 40 seconds, and 72°C for 90 seconds, with a final extension 
at 72°C for 7 minutes. Sequence variants were identified on 
chromatograms, which detected six SNPs (–47 T>C, –20 T>C, 
Arg16gly A>G, Gln27Glu C>G, Leu134 Leu G>A, and Arg175Arg 
C>A). The SNP genotypes were verified by direct sequencing of 
the PCR products.
Statistical analysis
The chi-square (χ2) test with one degree of freedom (df) was 
used to test the frequency of each SNP for significant departure 
from Hardy-Weinberg equilibrium. Differences in genotypic fre-
quency between patients or exposed and control subjects were 
examined by the χ2 test. To evaluate the genetic associations 
among the TDI-OA, AEC, and NC groups, logistic regression 
models (codominant, dominant, and recessive) were used to 
analyze SNPs and haplotypes after controlling for age and gen-
der as covariates. Subject haplotypes from ADRB2 polymor-
phisms were estimated using the hapassoc package in R 2.9.0,
23 
based on an estimation-maximization algorithm (EM). Linkage 
disequilibrium between loci was measured with the logarithm 
of odds (LOD) score. Logistic regression controlling for age and 
gender as covariates was applied to predict the genetic effects of 
ADRB2 haplotypes for IgE sensitization to TDI-HSA conjugate 
using the null haplotype as the reference. The P-values were 
corrected by false discovery rate (FDR, R2.7.1; R foundation for 
Statistical Computing, Vienna, Austria), which is a statistical 
means to correct for confounding effects of multiple genetic and 
clinical factors. Associations are expressed as adjusted logistic 
odds ratio (OR) and 95% confidence intervals (95% CI). Student’s 
t test was used to compare continuous variables (values are ex-
pressed as means±standard deviation [SD]). Categorical vari-
ables were compared using the χ2 test or Fisher’s exact test. Con-
tinuous variables without a normal distribution were log-trans-
formed and presented on their original scale. Statistical analy-
ses were performed with SPSS ver. 12.0.1 (SPSS Inc., Chicago, IL, 
USA). In all analyses, P<0.05 was taken to indicate statistical sig-
nificance.
 
RESULTS
Demographics of the study population
The demographic data of TDI-OA patients (n=103), AEC indi-
viduals (n=60), and unexposed healthy controls (NC; n=263) 
are shown in Table 1. There were no significant differences in 
mean age, gender distribution, or serum total IgE levels between 
the TDI-OA and AEC groups. Exposure durations were signifi-
cantly longer in the AEC group than in the TDI-OA group. Metha-
choline challenge testing was not performed in participants in 
the AEC and NC groups because these healthy individuals re-
ported no respiratory symptoms.
Allele, genotype, and haplotype frequencies of the beta 
2-adrenergic receptor gene
A genetic association study of six SNPs (–47 T>C, –20 T>C, Ar-
g16Gly A>G, Gln27Glu C>G, Leu134Leu G>A, and Arg175Arg 
C>A) was performed in the three study groups (Table 2). The al-
lele and genotype frequencies were consistent with previous 
studies in Korean populations.
24,25 There were no significant dif-
ferences in allelic, genotypic, or haplotypic frequencies of the six 
SNPs among the study groups. The six SNPs of ADBR2 polymor-
phisms were in linkage disequilibrium (LOD score >3, Figure); 
four haplotypes including ht1 [TTACGC], ht2 [TTGCAA], ht3 
[CCGGGC], and ht4 [TTGCGC] were constructed with the EM 
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Figure.  Linkage disequilibrium plot of ADRB2 6 polymorphisms using the con-
fidence bounds color scheme of Haploview 3.32. Dark grey, light grey, and 
white blocks indicate strong evidence for linkage disequilibrium, uninformative, 
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algorithm, but both ht3 and ht4 had a frequency of less than 5%. 
There were no significant differences in genotype distributions 
of the four ADRB2 haplotypes among the three groups (Table 2).
Effects of ADBR2 polymorphisms on the clinical parameters in 
patients with TDI exposure
We compared the clinical parameters in TDI-exposed subjects 
(TDI-OA and AEC groups) according to the six ADBR2 SNPs to 
assess the relationship between ADBR2 polymorphisms and the 
TDI-OA phenotype (Table 3). There were no significant differ-
ences in asthma duration, baseline FEV1, PC20, or total serum 
IgE levels among the genotypes of the six SNPs (data not shown).
Among the three analysis models (codominant, dominant, and 
recessive models), the ADRB2, Arg16Gly, Leu134Leu, and Ar-
g173Arg polymorphisms showed highly significant effects on 
the prevalence of serum specific IgE to the TDI-HSA conjugate, 
with the highest significance observed in the codominant mod-
el (OR, 3.09; 95% CI, 1.47–6.51 for Arg16Arg A>G, OR, 2.42; 95% 
CI, 1.16–5.07 for Leu134Leu G>A and OR, 2.97; 95% CI, 1.39–6.32 
for Arg173Arg C>A) (Table 3). Of the six SNPs, only the Arg16Gly 
A>G polymorphism had a significant association with IgE sensi-
tization to the TDI-HSA conjugate under all three modes of in-
heritance. This effect was significant after correction for multiple 
hypothesis testing (P=0.038 for the codominant model, P=0.041 
Table 2.  Genotype, allele, and haplotype frequencies of the β2-adrenergic receptor gene (ADRB2)
Loci
Genotype/ 
Haplotype
TDI-OA
(n=103) (%)
TDI AEC
(n=60) (%)
NC
(n=263) (%)
TDI-OA vs. AEC
OR (95% CI)*
TDI-OA vs. NC
OR (95% CI)*
-47 T>C TT 92 (91.1) 54 (93.1) 225 (87.5) 0.68 (0.218-2.149) 1.35 (0.621-2.941)
CT 8 (7.9) 4 (6.9) 31 (12.1) NA 0.49 (0.109-2.26)
CC 1 (1.0) 0 (0) 1 (0.4) 0.85 (0.46-1.58) 1.25 (0.818-1.895)
-20 T>C TT 92 (91.1) 55 (94.8) 224 (87.8) 0.53 (0.147-1.876) 1.34 (0.615-2.92)
CT 8 (7.9) 3 (5.2) 30 (11.8) NA 0.50 (0.109-2.264)
CC 1 (1.0) 0 (0) 1 (0.4) 0.73 (0.372-1.446) 1.24 (0.814-1.888)
Arg16Gly AA 30 (29.7) 14 (23.3) 84 (32.1) 1.43 (0.897-2.282) 0.94 (0.663-1.333)
A>G AG 53 (52.5) 28 (46.7) 125 (47.7) 1.40 (0.956-2.039) 1.09 (0.796-1.505)
GG 18 (17.8) 18 (30.0%) 53 (20.2) 1.15 (0.794-1.671) 0.87 (0.663-1.142)
Gln27Glu CC 93 (91.2) 56 (94.9) 224 (86.5) 0.50 (0.14-1.807) 1.49 (0.685-3.238)
C>G CG 8 (7.8) 3 (5.1) 34 (13.1) NA 0.49 (0.107-2.273)
GG 1 (1.0) 0 (0) 1 (0.4) 0.72 (0.363-1.412) 1.31 (0.865-1.992)
Leu134Leu GG 41 (41.4) 20 (33.9) 110 (42.0) 1.33 (0.845-2.103) 0.91 (0.633-1.297)
G>A AG 44 (44.4) 26 (44.1) 118 (45.0) 1.30 (0.852-1.978) 0.97 (0.676-1.39)
AA 14 (14.1) 13 (22.0) 34 (13.0%) 1.16 (0.828-1.631) 0.92 (0.714-,1.186)
Arg175Arg CC 41 (41.0) 19 (32.2) 109 (43.8) 1.46 (0.93-2.298) 0.85 (0.592-1.211)
C>A AC 45 (45.0) 25 (42.4) 107 (43.0) 1.44 (0.954-2.166) 0.95 (0.663-1.362)
AA 14 (14.0) 15 (25.4) 33 (13.3) 1.20 (0.856-1.693) 0.87 (0.672-1.12)
ht1 ht1/ht1 29 (28.2) 12 (20.0) 83 (31.6) 1.54 (0.96-2.475) 0.93 (0.657-1.313)
[TTACGC] ht1/- 55 (53.4) 29 (48.3) 125 (47.5) 1.43 (0.986-2.074) 1.12 (0.817-1.529)
-/- 19 (18.4) 19 (31.7) 55 (20.9) 1.22 (0.832-1.801) 0.84 (0.639-1.105)
ht2 ht2/ ht2 13 (12.6) 11 (18.3) 32 (12.2) 0. 80 (0.504-1.265) 1.13 (0.785-1.614)
[TTGCAA] ht2/- 46 (44.7) 27 (45) 118 (44.9) 0.89 (0.642-1.243) 1.09 (0.845-1.393)
-/- 44 (42.7) 22 (36.7) 113 (43.0) 0.81 (0.519-1.252) 1.07 (0.742-1.548)
ht3 ht3/ ht3 0 (0) 0 (0) 1 (0.4) 2.50 (0.508-12.286) 0.62 (0.265-1.466)
[CCGGGC] ht3/- 8 (7.8) 2 (3.3) 32 (12.2) 1.58 (0.713-3.505) 0.79 (0.514-1.218)
-/- 95 (92.2) 58 (96.7) 230 (87.5) NA NA
ht4 ht4/ ht4 2 (1.9) 0 (0) 1 (0.4) 0.81 (0.314-2.073) 1.47 (0.608-3.547)
[TTGCGC] ht4/- 5 (4.9) 7 (11.7) 8 (3) 0.76 (0.432-1.33) 1.23 (0.719-2.122)
-/- 96 (93.2) 53 (88.3) 254 (96.6) NA 1.59 (0.431-5.891)
*Each OR (95% CI) was calculated using the co-dominant, dominant, and recessive models. Logistic regression analysis was used to control age and sex as covari-
ates. Haplotypes with a frequency >1% are listed.
TDI-OA, toluene diisocyanate-induced asthma patients; AEC, asymptomatic exposed controls; NC, unexposed normal controls; n, number of subjects; OR, odds ratio; 
95% CI, 95% confidence interval; NA, not available.Ye et al. Volume 2, Number 4, October 2010
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for the recessive model). Homozygous ADRB2 ht1/ht1 showed 
a significantly higher prevalence of specific IgE to TDI-HSA con-
jugate compared with the null ht1 (P=0.048; OR, 15.40; 95% CI, 
1.81–131.06; Table 3). However, the ADRB2 ht2 haplotype was 
not significantly associated with IgE sensitization to the TDI-HSA 
conjugate in this study. The statistical power (type I error=0.05) 
for evaluating the specific IgE to TDI-HSA conjugate association 
with genetic polymorphisms (ADRB2 Arg16Gly A>G and Ar-
g175Arg C>A and ht1 [TTACGC] was 0.795, 0.745, and 0.858, re-
spectively.
No significant differences were observed with serum specific 
IgG antibody.
Homozygotes for the ADRB2 Arg16 allele or haplotype 1 [TTAC-
GC] tended to show lower PC20 methacholine than Gly16 ho-
mozygotes among TDI-OA patients (homozygous for Arg16, 3.1 
±5.3 mg/mL vs. homozygous for Gly16, 9.3±17 mg/mL; P>0.05) in 
terms of airway hyperresponsiveness assessed by the metha-
choline bronchial challenge test. However, there was no signifi-
cant relation between the genotypes or haplotypes of the six 
ADRB2 SNPs and the degree of airway hyperresponsiveness.
DISCUSSION
We screened the genotypic and allelic frequencies of six ADBR2 
SNPs, including the two most common sites, Arg16Gly and 
Gln27Glu, in the present study. We identified significant associ-
ations between the frequencies of the Arg16Gly and Arg173Arg 
SNPs and the ht1 [TTACGC] haplotype and the prevalence of 
specific IgE antibodies to the TDI-HSA conjugate among TDI-
exposed participants. Several genetic factors have recently been 
identified that may alter OA risk. The present study is the first to 
investigate a possible association between ADBR2 polymorphi-
Table 3.  Comparison of the prevalence of specific IgE antibodies to TDI-HSA conjugates stratified by the genotypes ADRB2 Arg16Gly A>G, Leu134Leu G>A, Ar-
g175Arg C>A and haplotypes ht1[TTACGC] and ht2[TTGCAA] in TDI-exposed workers, including both TDI-induced asthma patients and asymptomatic exposed con-
trols (n=130)
Loci
Genotype/
Haplotype
IgE to TDI-HSA
P value* OR (95% CI) Pc
†
Positive (n=23) (%) Negative (n=107) (%)
-47 T>C TT 23 (100) 96 (93.2) 0.999 NA 0.999
TC 0 7 (6.8)
CC 0 0
-20 T>C TT 23 (100) 97 (94.2) 0.999 NA 0.999
TC 0 6 (5.8)
CC 0 0
Arg16Gly A>G AA 11 (47.8) 22 (20.8) 0.003 3.09 (1.47-6.51) 0.038
AG 11 (47.8) 55 (51.9) 0.038 2.97 (1.06-8.32) 0.095
GG 1 (4.3) 29 (27.4) 0.011 1.86 (1.15-2.99) 0.041
Gln27Glu C>G CC 23 (100) 99 (94.3) 0.999 NA 0.999
CG 0 6 (5.7) 0.999
GG 0 0 0.999
Leu134Leu G>A GG 12 (52.2) 31 (30.1) 0.019 2.42 (1.16-5.07) 0.057
AG 10 (43.5) 51 (49.5) 0.086 2.48 (0.88-7.02) 0.143
AA 1 (4.3) 21 (20.4) 0.047 1.60 (1.01-2.56) 0.101
Arg175Arg C>A CC 13 (56.5) 29 (28.2) 0.005 2.97 (1.39-6.32) 0.038
AC 9 (39.1) 51 (49.5) 0.056 2.76 (0.97-7.83) 0.105
AA 1 (4.3) 23 (22.3) 0.011 1.85 (1.15-2.97) 0.041
ht1 [TTACGC] ht1/ht1 10 (43.5) 20 (18.7) 0.012 15.40 (1.81-131.06) 0.048
ht1/- 12 (52.2) 57 (53.3) 0.078 6.60 (0.81-53.73) 0.087
-/- 1 (4.3) 30 (28.0) R
ht2 [TTGCAA] ht2/ht2 1 (4.3) 18 (16.8) 0.064 0.13 (0.02-1.13) 0.087
ht2/- 9 (39.1) 55 (51.4) 0.087 0.43 (0.17-1.13) 0.087
-/- 13 (56.5) 34 (31.8) R
*Each OR (95%CI) for the genetic association of six SNPs was calculated using the co-dominant, dominant, and recessive models. Logistic regression analysis was 
used to control age and sex as covariates. 
†Pc was calculated using the False Discovery Rate method to adjust for multiple testing. TDI-HSA, TDI conjugated with hu-
man serum albumin; ADRB2, β2-adrenergic receptor gene; n, number of subjects whose serum specific IgE to TDI-HSA was measured; OR, odds ratio; 95% CI, 95% 
confidence interval; NA, not available; ht1, haplotype 1; ht2, haplotype 2; R, reference genotype.ADRB2 Polymorphisms in TDI-Induced Asthma AAIR 
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sms and a specific phenotype of adult-onset OA in a Korean 
population. Our data suggest that the ADBR2 haplotype ht1 
[TTACGC], including the Arg16 allele, contributes to the devel-
opment of specific IgE sensitization to TDI among TDI-exposed 
Korean workers.
The β2-adrenergic receptor is a G protein-coupled receptor that 
mediates catecholamine actions in multiple human tissues. β2-
adrenergic receptors are present on the surface of inflammato-
ry cells and may modulate signaling pathways in these cells. β2-
adrenergic receptor stimulation could induce increased IgE pro-
duction by human B lymphocytes; it may also enhance produc-
tion and expression of soluble, high-affinity IgE receptor (sCD23), 
suggesting that this receptor agonist may be involved in IgE syn-
thesis.
26 The anti-inflammatory effects of β2-agonists may inhib-
it the elaboration of mediators from mast cells.
27 Several studies 
have demonstrated that altered β2-adrenergic receptor signal-
ing due to the ADBR2 polymorphisms Arg16Gly and Gln27Glu 
could potentially affect airway smooth muscle contractility and 
inflammatory cytokine production, and therefore modulate IgE 
production through β2-adrenergic receptors expressed on B and 
T lymphocytes in vitro and in vivo.
28-30 A previous study demon-
strated that increased adrenoceptor downregulation was related 
to the ADRB2 Arg16Gly polymorphism.
31 However, other stud-
ies have not identified significant associations between the Gly-
27Glu or Arg16Gly ADRB2 polymorphisms and total serum IgE 
levels in Korean populations.
17,25,32 Llanes et al.
33 did not identify 
significant associations between genetic variations of ADRB2 
Arg16Gly polymorphisms and the risk of olive pollen sensitiza-
tion and asthma. Conversely, Ramsay et al.
34 reported that the 
ADBR2 Arg16Gly polymorphism (Arg16 variants) was associat-
ed with a significantly increased specific IgE level and increased 
wheal size in response to skin prick testing with Ascaris lumbri-
coides in a Venezuelan cohort, although no significant associa-
tions were identified between physician-diagnosed asthma and 
ADRB2 genetic polymorphisms in the same population.
It is generally accepted that TDI exposure can induce specific 
IgE, resulting in TDI-OA.
3,21,22,35 We detected IgE with the 80% 
vapor-type TDI-HSA conjugate in the present study, and dem-
onstrated a significant association with the ADBR2 Arg16Gly 
AA/AG genotype and ht1 [TTACGC]; these observations sug-
gested that this genotype could serve as a risk factor for increased 
specific IgE sensitization in TDI-exposed workers and could ul-
timately contribute to the development of asthmatic symptoms. 
However, the mechanism by which the ADBR2 polymorphism 
induced IgE sensitization to inhaled TDI is still unclear. It is pos-
sible that β2-adrenergic receptors on inflammatory cells from 
subjects with the haplotype 1 [TTACGC] of ADBR2 polymor-
phisms, and particularly the ADRB2 Arg16Gly AA genotype, are 
more susceptible to the generation of serum specific IgE anti-
bodies in response to inhaled TDI.
Our study had possible limitations considering the issue of mul-
tiple comparisons. The six ADRB2 SNPs evaluated in the present 
study had moderate levels of linkage disequilibrium and were 
thus not fully independent tests. In this case, if strict Bonferroni 
correction was applied to the multiple comparisons for a single 
genetic polymorphism, false negative rates usually increased. 
Therefore, an alternative adjustment for multiple hypothesis 
testing is to use the FDR method, which estimates the likelihood 
that our findings are false.
36 Regardless of FDR adjustments, ev-
idence of significant associations among ADRB2 Arg16Gly, Ar-
g175Arg, and ht1 with the prevalence of specific IgE to TDI-HSA 
conjugate remain.
OA is a complex disease characterized by multiple genetic and 
environmental factors. We attempted to reduce environmental 
effects on the asthma phenotype in the present study by enroll-
ing healthy, asymptomatic exposed controls. After adjusting for 
age, gender, and other ADRB2 SNPs, the ht1 [TTACGC] haplo-
type, composed of all wild genotypes of Arg16Gly, Leu134Leu, 
and Arg175Arg among the six ADRB2 SNPs, was significantly 
associated with specific IgE sensitization in TDI-exposed work-
ers. Additional environmental factors, including inhaled aero-
allergen exposure, smoking, and viral infections, must undergo 
further evaluation.
37 Therefore, further studies are required to 
evaluate the associations between ADRB2 polymorphisms and 
TDI-OA pathogenesis and to better elucidate the complex inter-
actions of ADRB2 polymorphisms with environmental or genet-
ic factors that may increase TDI-OA susceptibility. Our results 
suggest that the ht1 haplotype, which includes all wild genotypes 
of Arg16Gly, Leu134Leu, and Arg175Arg, may be a risk factor for 
developing specific IgE sensitization to TDI.
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